S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Keros Therapeutics Authorizes Up to $5 Million Share Buyback

Keros Therapeutics’ board approved a share buyback of up to $5 million after the company received a $20 million development milestone payment from Takeda Pharmaceuticals under a licensing agreement.

Keros Therapeutics Authorizes Up to $5 Million Share Buyback

The payment is tied to elritercept, which Keros is developing as a blood platelet producer. The drug reached a clinical-trial milestone with the first patient completing dosing.

Keros said the buyback authorization may be modified or discontinued at any time.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!